Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07054894 in Healthy Adults
NCT04388878Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) and psoriasis comparing PF-07054894 with Placebo (2 arms). Primary endpoints: AEs following Single ascending dose (SAD), AEs following multiple ascending dose (MAD) and 3 more. Started Jul 2020; status: completed.
02
Drugs
PF-07054894
03
Conditions
ulcerative colitis (UC)psoriasis
Beyond the preview
Go deeper on NCT04388878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388878.